A Phase 2a, Open-Label Pilot Study to Evaluate the Safety/Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants with Recurrent Pericarditis

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524784-20-00

Enrollment

Registered

2026-02-27

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Pericarditis

Brief summary

Incidence and severity of AEs, SAEs, and AEs leading to study treatment discontinuation from the first dose through end of the Follow-Up Period.

Detailed description

Change from baseline in NRS over time through Week 6; Percent change from baseline in NRS over time through Week 6, Change from baseline in hs-CRP over time through Week 6 ; Percent change from baseline in hs-CRP over time through Week 6; Change from baseline in hs-CRP over time through Week 6 in participants with baseline CRP > 10 mg/L ; Percent change from baseline in hs-CRP over time through Week 6 in participants with baseline CRP > 10 mg/L

Interventions

None listed

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence and severity of AEs, SAEs, and AEs leading to study treatment discontinuation from the first dose through end of the Follow-Up Period.	—

Secondary

Measure	Time frame
Change from baseline in NRS over time through Week 6; Percent change from baseline in NRS over time through Week 6, Change from baseline in hs-CRP over time through Week 6 ; Percent change from baseline in hs-CRP over time through Week 6; Change from baseline in hs-CRP over time through Week 6 in participants with baseline CRP > 10 mg/L ; Percent change from baseline in hs-CRP over time through Week 6 in participants with baseline CRP > 10 mg/L	—

Measure

Time frame

—

Outcome results